Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 and 5 receptor modulator in development for ulcerative colitis and Crohn’s disease. Ozanimod is also being studied for the treatment of multiple sclerosis.
Selective binding with S1PR1 receptors is hypothesized to withhold a specific subset of lymphocytes in lymph nodes, and thus to reduce their numbers in the circulatory system. The result is a reduction of pro-inflammatory lymphocytes circulating to sites of inflammation.
Importantly, immune surveillance is maintained.
Ozanimod is an oral investigational medication.
Ozanimod is an investigational compound that is not approved for any use in any country.
Get Involved In A Study
Call 866-914-6999 or click the button below to learn more!